. Author manuscript; available in PMC: 2012 Jan 15.

Published in final edited form as: J Immunol. 2011 Jun 15;187(2):654–663. doi: 10.4049/jimmunol.1003941

Table I. OKT8 increases tetramer staining of MEL5 and MEL187.c5 CD8⁺ T-cells with low affinity pMHCI ligands.

Summary of equilibrium binding analysis of MEL5 and MEL187.c5 TCRs with pMHCI variants, and the effect of OKT8 on HLA A*0201 tetramer staining. Raw SPR data are shown in Figure S3; flow cytometry data are shown in Figure S4. MFI, median fluorescence intensity.

Peptide	MEL5 K_D (μM)	MEL5 Tetramer only (MFI)	MEL5 OKT8 + Tetramer (MFI)	MEL187 K_D (μM)	MEL187 Tetramer only (MFI)	MEL187 OKT8 + Tetramer (MFI)
ELAGIGILTV	17 ± 1	855	917	18 ± 1	353	418
FLAGIGILTV	92 ± 1	194	227	30 ± 2	300	373
ELTGIGILTV	82 ± 4	36	87	37 ± 1	128	181
ELAGIGIITV	77 ± 3	123	236	36 ± 3	195	257
FLAGIGIITV	75 ± 3	367	426	47 ± 2	246	311

Table I. OKT8 increases tetramer staining of MEL5 and MEL187.c5 CD8+ T-cells with low affinity pMHCI ligands.

Table I. OKT8 increases tetramer staining of MEL5 and MEL187.c5 CD8⁺ T-cells with low affinity pMHCI ligands.